Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
PRESENTATION | Finance

3Q24 Wrap: Lookin’ up at last

Winners, losers in biotech stock tiers in 3Q24

By Meredith Durkin Wolfe, Director of Research
October 4, 2024 10:20 PM UTC

Biopharma stocks ticked up in 3Q24 across all market cap tiers, with all but microcaps rising double digits. The $1-$4.9 billion market cap band led, with a 14% median increase. 

Adding to growth in 2Q24, the top two tiers — those starting the quarter at $5 billion or above — are now in the black for the year. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

4d Molecular Therapeutics Inc.

Beigene Ltd.

Cassava Sciences Inc.

Hillevax Inc.

Instil Bio Inc.

Madrigal Pharmaceuticals Inc.

Moderna Inc.